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Acute disseminated encephalomyelitis (ADEM) is characterized by its rapid progression
with variable symptoms and severity in adults and children. Multiple therapeutic options
have been proposed, but solid evidence is yet to be gathered. We describe an adult man
with a fulminant form of ADEM unresponsive to numerous treatment modalities.
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CASE PRESENTATION
A 60-year-old man was brought to the emergency room due to
family concerns of rapid cognitive decline. Two weeks prior to
hospitalization, he had an elective dental procedure. Immediately
following the procedure, he complained of headaches, nausea,
vomiting, intermittent fevers, and chills. He received one dose of
intramuscular ceftriaxone, and daily oral amoxicillin and metron-
idazole. A week before admission to our hospital, he became pro-
gressively weaker, less communicative, and repeated non-sensical
words.
Medical history was remarkable for arterial hypertension and
dyslipidemia. Medications were simvastatin, amlodipine, and
olmesartan.
Upon arrival to our hospital, he was afebrile, with normal
blood pressure, heart rate, and oxygen saturation. He was alert
and oriented only to person. Language was non-fluent. He was
unable to follow commands, had moderate neck stiffness, moved
all his extremities spontaneously, and responded appropriately to
nociceptive stimuli.
Blood work showed hemoglobin (Hgb) of 12.5 g/dl, white
blood cells (WBC) of 8.3 k/UL (85% granulocytes), and a platelet
count of 263 k/UL. Basic metabolic profile (BMP) liver enzymes,
albumin, bilirubin, and urine drug screen were unremarkable.
Cranial computed tomography (CCT) was unremarkable. Empir-
ical intravenous (IV) acyclovir 600 mg every 8 h, ceftriaxone 2 g
every 12 h, vancomycin 1000 mg every 12 h, and metronidazole
500 mg every 6 h were started. A lumbar puncture (LP) showed
an opening pressure of 7 cm of cerebrospinal fluid (CSF), 278
red blood cells (RBC), 84 WBC (88% lymphocytes), glucose con-
tent of 59 mg/dl, and a protein content of 91 mg/dl. CSF PCR
for Herpes simplex virus (HSV) type 1 and 2, Epstein Barr virus
(EBV), Cytomegalovirus (CMV), Enterovirus, Lyme antibodies,
and cultures were negative. Antimicrobials were discontinued after
a total of 7 days.
He was admitted to the Neuroscience Intensive Care Unit
(NICU). As his mental status further deteriorated, he was electively
intubated for airway protection. EEG showed continuous spikes
in the left frontal region. He received IV lorazepam 2 mg, and
was started on IV levetiracetam 1000 mg every 12 h. He was
placed on continuous video EEG monitoring for 48 h with no evi-
dence of epileptiform activity. Magnetic resonance imaging (MRI)
of the brain with gadolinium showed multiple rounded lesions
throughout the brain parenchyma predominantly involving the
white matter of both cerebral hemispheres, basal ganglia, mid-
brain, and pons. Some of these lesions showed enhancement in a
linear and nodular pattern (Figure 1). Transesophageal echocar-
diogram (TEE) showed no sources of emboli or vegetations. Serial
blood and urine cultures were negative. A presumptive diagnosis of
ADEM was made, and he received methylprednisolone IV 1000 mg
daily for 5 days and IV immunoglobulin (IVIG) 0.4 g/kg/dose daily
for 5 days were concomitantly started. Due to the lack of improve-
ment with IVIG, he received five sessions of plasma exchange
(PLEX) every other day, starting the day after the last dose of
IVIG. Despite this, the patient remained unresponsive to ver-
bal stimuli, with preserved pupillary and oculocephalic reflexes
and minimal arm flexion on noxious stimuli on the left arm.
His exam remained unchanged during his hospital stay. Fourteen
days after admission, a repeat MRI of the brain showed more
disseminated white matter lesions (Figure 2). Stereotactic brain
biopsy showed numerous cluster differentiation (CD) 68 posi-
tive cells with focal CD3 (T cell) and CD20 (B-cell) perivascular
inflammatory infiltrates. The affected parenchymal areas con-
tained both CD4 positive and CD8 positive T cells with the latter
in greater number. Luxol Fast Blue stains showed demarcated areas
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FIGURE 1 | MRI (FLAIR) shows multiple rounded lesions throughout
the brain parenchyma predominantly involving the white matter of
both cerebral hemispheres, basal ganglia and midbrain.
FIGURE 2 | MRI (FLAIR) shows increased number of supra and
infratentorial lesions.
of coalescencing perivenous demyelination with relative sparing of
axons with some axonal swellings (Figure 3). Simian Virus (SV) 40
polyoma virus, Gram, and AFB stains were negative. Although the
PAS stain without diastase was negative, the PAS with diastase stain
showed questionable rod-shaped bacteria. He received another
6-day course sulfamethoxazole with trimethoprim 800–160 mg
every 12 h. Subsequent bacterial PCR for tissue and serum were
negative for Tropheryma whipplei. He then received IV Cyclophos-
phamide 750 mg/m2/dose. H. Subsequently, one dose of Ritux-
imab 375 mg/m2/dose was given without significant change in his
overall neurological condition. He was discharged after 30 days
from the hospital to a long term acute care hospital where his con-
dition remained unchanged, in a persistent vegetative state after
6 months, when this report was initially submitted.
LITERATURE REVIEW
ADEM is a monophasic immune-mediated inflammatory dis-
order of the central nervous system (CNS) affecting predom-
inantly the white matter of the brain, brainstem, and spinal
cord. ADEM is more commonly seen in the pediatric popula-
tion with a mean age of onset in this population of 4.5–7.5 years
(1), and 33.5 years in adults (2). ADEM has been associated
with numerous immunological triggers mainly viral infections or
FIGURE 3 | Luxol Fast Blue stain shows areas of demyelination with
relative sparing of the axons with some axonal swellings.
vaccinations, although in approximately one-third of cases in chil-
dren and in approximately half of adults, ADEM showed no clear
associations (3).
Diagnostic criteria for ADEM have been proposed (4), but the
great overlap with the initial presentation of multiple sclerosis
continues to present a challenge for the diagnosis without tissue
confirmation.
Clinical presentation is usually characterized by acute onset
encephalopathy associated with multifocal neurologic deficits.
There is often a prodromal phase with fever, malaise, headaches,
nausea, and vomiting, followed by meningismus. If an immuno-
logic trigger is present, it usually precedes the presentation by
2–30 days (1). Presentation varies according to where the lesions
are located. Compromise of cortical gray matter, basal ganglia (2),
and bilateral optic nerve involvement are more frequent in ADEM
compared to MS (5). Peripheral nervous system compromise can
be present in up to 43% of the cases in adults (6).
Cerebrospinal fluid is usually normal or may show a mild lym-
phocytic pleocytosis, unlike MS. Oligoclonal bands (OCB) are
present in 20–58% of adults compared to 85% in MS (2, 7). Some
studies suggest that in ADEM, the presence of OCB is a transient
phenomenon (6).
Magnetic resonance imaging in ADEM typically presents with
large multiple and asymmetric lesions involving cortical, gray
white matter junction, and central white matter as well as cerebel-
lum, brainstem, and spinal cord (8). Involvement of the thalami
and basal ganglia while infrequent is rather characteristic of ADEM
(2). The extension of the lesions, particularly involvement of the
brainstem has been associated with worse prognosis (9). As lesions
may evolve during weeks, the pattern of enhancement may be
inconsistent, with up to one-third of patients showing some lesions
without associated enhancement (2, 10, 11).
ADEM is pathologically characterized by the perivenular infil-
trates of T cells and macrophages associated with perivenular
demyelination with limited sleeves of demyelination (12–14)
unlike the confluent areas of demyelination seen in MS.
Clinical course of ADEM is considered in general to be favorable
with reports of spontaneous improvement, although permanent
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disability and death have also been reported. Clinical outcome
is in general more severe in adults compared to children (15).
Impaired consciousness and occurrence of seizures have been asso-
ciated with poor prognosis (16, 17). Complete motor recovery
ranges between 15 and 46% in adults (2), 20% relapse within
2 years (15).
Initial management consists of high-dose IV corticosteroids fol-
lowed by tapering with oral corticosteroids (18, 19). If no improve-
ment is noticed after a course of corticosteroids is completed, other
therapeutic options should be considered. Multiple reports and
studies have reflected clinical improvement after administration
of IVIG, especially when an infectious trigger is identified (20,
21). Clinical improvement after IVIG administration can be seen
from the initial course up to 3 weeks (21, 22). Plasmapheresis
has also been shown to improve outcome in randomized tri-
als (23, 24). The clinical response after four to six sessions of
plasmapheresis in refractory cases is usually seen after 3 days of
starting therapy (25–27). These therapeutic options have been
used individually or in combination (28). Other immunomodu-
latory agents as cyclophosphamide and rituximab have been used
in the management of other fulminant demyelinating diseases (7,
29). Other non-pharmacological measures such as decompressive
hemicraniectomy and hypothermia have reported effective in ful-
minant cases (30,31). Currently, there are no data from prospective
randomized trials for the management of ADEM in children or
adults.
In our case, considering that the half-life of IVIG ranges
between 22 and 96 days, the patient might not have had enough
exposure to IVIG before it was removed from the system by
the plasmapheresis, precluding him from receiving the full ben-
efit of IVIG. However, given his deteriorating clinical course and
that time was of the essence, starting plasmapheresis sooner was
considered a sound clinical decision.
SUMMARY
We report an adult with fulminant presentation of ADEM with
no clinical or radiological evidence of improvement despite
multimodal aggressive parenteral therapy.
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